An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch.
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Rotigotine (Primary) ; Rotigotine
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Cmic; Shandong Luye Pharmaceutical
- 02 Feb 2021 New trial record
- 15 Jan 2021 Results published in the Luye Pharma's Media Release